⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIRM News
Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
businesswire.com
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
businesswire.com
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
MIRM
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
businesswire.com
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
businesswire.com
MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
businesswire.com
MIRM
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
businesswire.com
MIRM